RESEARCH CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease (Filmed 2024)
Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.
The condition is strongly linked with the development of Type 2 diabetes, heart disease, and various liver-related consequences. Dr. Keating’s research emphasises lifestyle interventions, particularly the role of exercise, in managing MASLD. Her work has shown that aerobic exercise, independent of weight loss, plays a crucial role in reducing liver fat and improving liver health.
Through clinical trials, Dr. Keating and her team have explored the impact of different doses of supervised aerobic exercise on individuals with obesity and MASLD. Their findings suggest that aerobic exercise, at various durations and intensities, yields benefits for reducing liver fat. They recommend 150 to 240 minutes of moderate to vigorous intensity aerobic exercise per week as beneficial for improving liver health. Moreover, even lower doses of exercise, such as 135 minutes per week, have shown positive effects.
Dr. Keating has collaborated with Exercise and Sports Science Australia and international experts in creating exercise guidelines for the management of MASLD, which have been adopted in numerous policies and guidelines worldwide. Currently, her focus is on designing tailored exercise solutions to help individuals living with MASLD sustain long-term exercise behaviours based on their needs, perspectives, and experiences.
* AES is the acronym for Accredited Exercise Scientist (AES), AEP is the acronym for Accredited Exercise Physiologist
-
Seeking discoveries in earlier bowel cancer detection
Associate Professor Susan Woods is a cancer research focused on eradicating bowel cancer through earlier detection and investigating the DNA related from colorectal cancer cells. She leads the Gut Cancer Research Group at the University of Adelaide and SAHMRI and with her team is researching new treatments for advanced disease.
-
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
-
Personalised approaches to lung therapy
Dr. Adams’ research focus is on lung cancer, which is the deadliest of all cancers worldwide. He is working towards developing personalised approaches to pinpoint a therapy that is going to be most effective for the person with that disease. Dr. Adams’ research is focusing on chemotherapy and targeted therapy, and he is trying to identify upfront which of those tumours are likely to be resistant to the therapy. He then identifies strategies that will resensitize or increase the sensitivity of the tumour to the standard of care that is targeted therapy or chemotherapy.
